<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>CYP2B6 is a highly variable and polymorphic <z:chebi fb="0" ids="38559">cytochrome P450</z:chebi> enzyme which plays a vital role in the degradation of some endogenous metabolites, <z:chebi fb="0" ids="35703">xenobiotics</z:chebi>, and harmful compounds </plain></SENT>
<SENT sid="1" pm="."><plain>The 516G&gt;T single nucleotide polymorphism (SNP) in exon 4 of CYP2B6 gene may change CYP2B6 enzyme activity and the gene expression in the liver </plain></SENT>
<SENT sid="2" pm="."><plain>Carcinogens' failure to be degraded by CYP2B6 may cause DNA injury and <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> </plain></SENT>
<SENT sid="3" pm="."><plain>Here, we aimed to evaluate the association between genotype or allele of CYP2B6 516G&gt;T SNP and <z:hpo ids='HP_0002488'>acute leukemia</z:hpo> and <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) </plain></SENT>
<SENT sid="4" pm="."><plain>We recruited 300 patients including 164 cases of <z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>), 96 cases of <z:hpo ids='HP_0006721'>acute lymphoblastic leukemia</z:hpo> (ALL, including 17 cases of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">T-ALL</z:e> and 79 cases of <z:e sem="disease" ids="C0023435" disease_type="Neoplastic Process" abbrv="">B-ALL</z:e>), 40 cases of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>, as well as 348 unrelated umbilical cord blood as the controls </plain></SENT>
<SENT sid="5" pm="."><plain>Karyotype analysis and multiplex reverse transcription-polymerase chain reaction (RT-PCR) was performed to determine different recurrent genetic abnormalities in these cases </plain></SENT>
<SENT sid="6" pm="."><plain>Genotype of CYP2B6 516G&gt;T SNP was determined by allele-specific primers PCR, and confirmed by gel electrophoresis and sequencing </plain></SENT>
<SENT sid="7" pm="."><plain>The GT and GT + TT genotype frequencies of c.516G&gt;T SNP were higher in ALL (37.5% and 42.7%, respectively, P &lt; 0.01), and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> (37.2% and 40.9%, respectively, P &lt; 0.01) than in control (23.9% and 25.9%, respectively) </plain></SENT>
<SENT sid="8" pm="."><plain>In the subtypes of <z:hpo ids='HP_0002488'>acute leukemias</z:hpo>, the GT + TT genotype frequency was significantly higher in <z:e sem="disease" ids="C1275661" disease_type="Neoplastic Process" abbrv="">AML with recurrent genetic abnormalities</z:e> (41.7%, p &lt; 0.05), in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>-NOS (40.6%, p &lt; 0.01), in <z:hpo ids='HP_0011009'>acute</z:hpo> monoblastic and monocytic <z:hpo ids='HP_0001909'>leukemia</z:hpo> (48.3%, p &lt; 0.01), and in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">T-ALL</z:e> (70.6%, p &lt; 0.01) as compared with those in the controls </plain></SENT>
<SENT sid="9" pm="."><plain>The frequency of CYP2B6 516 T allele was higher in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> (22.3%, p &lt; 0.01) and ALL (24.0%, p &lt; 0.01) compared with cord blood (13.9%) </plain></SENT>
<SENT sid="10" pm="."><plain>In different types of <z:hpo ids='HP_0002488'>acute leukemias</z:hpo>, CYP2B6 516 T allele frequency was significantly higher in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> with AML1-<z:chebi fb="0" ids="27561">ETO</z:chebi> (19.2%, p &lt; 0.05), <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>-NOS (22.7%, p &lt; 0.01), <z:hpo ids='HP_0011009'>acute</z:hpo> monoblastic and monocytic <z:hpo ids='HP_0001909'>leukemia</z:hpo> (25.9%, p &lt; 0.01), and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">T-ALL</z:e> (38.2%, p &lt; 0.01) </plain></SENT>
<SENT sid="11" pm="."><plain><z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> was unrelated to the genotype and allele frequencies of c.516G&gt;T SNP in CYP2B6 </plain></SENT>
<SENT sid="12" pm="."><plain>T allele of CYP2B6 516G&gt;T SNP may be one of the risk factors predisposing to the pathogenesis of a majority of ALL and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>, but has no relationship with <z:e sem="disease" ids="C0023435" disease_type="Neoplastic Process" abbrv="">B-ALL</z:e> and <z:hpo ids='HP_0001909'>leukemia</z:hpo> with or without chromosome abnormalities </plain></SENT>
</text></document>